As filed with the
Securities and Exchange Commission on September 23, 2024
Registration No. 333-280191
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO
Form F-1
REGISTRATION STATEMENT UNDER THE SECURITIES
ACT OF 1933
WEARABLE DEVICES LTD.
(Exact name of registrant as specified in its
charter)
State of Israel |
|
3873 |
|
Not Applicable |
(State or other jurisdiction of
incorporation or organization) |
|
(Primary Standard Industrial
Classification Code Number) |
|
(I.R.S. Employer
Identification Number) |
5 Ha-Tnufa St. |
|
Mudra Wearable, Inc. |
Yokne’am Illit, 2066736 Israel |
|
24A Trolley Square #2203 |
Tel: +972.4.6185670 |
|
Wilmington, DE 19806 |
(Address, including zip code, and telephone number, |
|
(Name, address, including zip code, and telephone |
including area code, of registrant’s principal executive offices) |
|
number, including area code, of agent for service) |
Copies to:
Oded Har-Even, Esq.
Howard Berkenblit, Esq.
Eric Victorson, Esq.
Sullivan & Worcester LLP
1251 Avenue of the Americas
New York, NY 10020
Tel: 212.660.3000 |
|
Reut Alfiah, Adv.
Gal Cohen, Adv.
Sullivan & Worcester
Tel-Aviv (Har-Even & Co.)
HaArba’a Towers
28 HaArba’a St.
North Tower, 35th Floor
Tel-Aviv, Israel 6473925
T +972.74.758.0480 |
Approximate date of commencement of proposed
sale to the public: As soon as practicable after the effective date hereof.
If any of the securities being registered on this
form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. ☒
If this form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering. ☐
If this form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. ☐
If this form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number
of the earlier effective registration statement for the same offering. ☐
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.
Emerging growth company ☒
If an emerging growth company that prepares its
financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards † provided pursuant to Section 7(a)(2)(B) of the Securities
Act. ☒
† |
The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012. |
The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act or until the registration statement shall become effective on such date as the Commission, acting pursuant to said Section 8(a),
may determine.
EXPLANATORY NOTE
This Post-Effective Amendment
No. 1, or this Post-Effective Amendment, to the Registration Statement on Form F-1 (File No. 333-280191), or the Registration Statement,
is being filed pursuant to our undertaking in the Registration Statement to update and supplement information contained in the Registration
Statement, as originally declared effective by the Securities and Exchange Commission, or the SEC, on June 24, 2024. The Registration
Statement originally covered the offer and sale of up to 24,574,209 ordinary shares,
NIS 0.01 par value per share, or Ordinary Shares, by YA II PN, LTD., a Cayman Islands exempt limited
partnership, or YA or the Selling Shareholder. The Selling Shareholder is a fund managed by Yorkville Advisors Global, LP.
The information included in
this filing updates and supplements the Registration Statement and the prospectus contained or incorporated therein. No additional securities
are being registered under this Post-Effective Amendment. Accordingly, this Post-Effective Amendment concerns only the offer and sale
of Ordinary Shares held by YA.
All filing fees payable to the SEC in connection with the registration
of these securities were previously paid in connection with the initial filing of the Registration Statement.
The information in
this prospectus is not complete and may be changed. The selling shareholder may not sell these securities until the registration statement
filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting
an offer to buy these securities in any state where the offer or sale is not permitted.
PROSPECTUS |
SUBJECT TO COMPLETION |
DATED SEPTEMBER 23, 2024 |
Up to 24,574,209 Ordinary Shares
Wearable Devices
Ltd.
This prospectus relates to
the offer and sale of up to 24,574,209 of our ordinary shares, NIS 0.01 par value per share, or the Ordinary Shares, by YA II PN, LTD.,
a Cayman Islands exempt limited partnership, or YA or the Selling Shareholder. The Selling Shareholder is a fund managed by Yorkville
Advisors Global, LP.
On June 6, 2024, we entered
into a Standby Equity Purchase Agreement, or the SEPA, with the Selling Shareholder, which provided for the sale of up to $10.0 million
of our Ordinary Shares. Of the $10.0 million eligible to be sold pursuant to the SEPA, or the Commitment Amount, to date we have sold
3,715,602 Ordinary Shares. In connection with the SEPA, we may request pre-paid advances of up to $10.0 million eligible to be sold pursuant
to the SEPA, or Commitment Amount, in an amount up to $3.0 million, each a Pre-Paid Advance. Each Pre-Paid Advance will be evidenced by
a promissory note, each, a Promissory Note. Each Promissory Note will fully mature 12-months following its issuance and shall accrue interest
on the outstanding principal balance thereon at a rate of 6% per annum, increasing to 18% per annum upon an Event of Default (as defined
in the Promissory Note). Beginning 60 days after the issuance of a Promissory Note, we shall pay to YA a monthly installment payment of
10% of the original principal amount of the Promissory Note and accrued interest, payable in cash or by submitting an Advance Notice (as
defined in the SEPA), where YA will offset the amount due to be paid to us under such notice against an equal amount of the monthly installment
amount, at our option. If we elect to pay in cash, the installment amount shall also include a payment premium in the amount of 5% of
the principal amount of the installment payment. The Promissory Note contains customary representations and warranties and events of default.
As of the date of this prospectus, we have requested and received a Pre-Paid Advance in the amount of $2.0 million on June 6, 2024, which
was evidenced by a Promissory Note issued on the same date. As of September 20, 2024, we have repaid $400 thousand of the principal amount
of such Promissory Note.
The Ordinary Shares being
offered by the Selling Shareholder may be issued pursuant to the SEPA. We are not selling any securities under this prospectus and will
not receive any of the proceeds from the sale of our Ordinary Shares by the Selling Shareholder. However, we may receive up to $10.0 million
in aggregate gross proceeds from sales of our Ordinary Shares to the Selling Shareholder that we may make under the SEPA, from time to
time after the date of this prospectus. Pursuant to the SEPA, we have issued to the Selling Shareholder an aggregate of 3,715,602 of our
Ordinary Shares for aggregate gross proceeds of approximately $1.7 million. Pursuant to the SEPA, we will issue to the Selling Shareholder
Ordinary Shares in an amount that is equal to 1.00% of the Commitment Amount, or the Commitment Fee, which will be issued in two tranches,
with 50% of the Commitment Fee due on the date that is 90 days from the date of the SEPA in an amount of Ordinary Shares equal to 50%
of the Commitment Fee divided by the average of the daily VWAP (as defined in the SEPA) of our Ordinary Shares during the three trading
days immediately prior to such first payment date and the remainder of the Commitment Fee due 180 days from the date of the SEPA in an
amount of Ordinary Shares equal to 50% of the Commitment Fee divided by the average of the daily VWAP (as defined in the SEPA) of our
Ordinary Shares during the three trading days immediately prior to such second payment date. On September 4, 2024, we and YA agreed to
postpone the issuance of the first tranche of the Commitment Fee and to issue the full 1.0% of the Commitment Fee to YA on the date that
is 180 days from the date of the SEPA. The Commitment Fee will be paid by the issuance to YA of such number of Ordinary Shares that is
equal to the balance of the Commitment Fee divided by the average of the daily VWAP of the Ordinary Shares during the three trading days
immediately prior to the payment date. The additional shares that may be offered pursuant to this prospectus would be purchased by the
Selling Shareholder pursuant to the SEPA at 97% of the market price, which is defined as the lowest daily volume weighted average price
of the Ordinary Shares during the three consecutive trading days commencing on the trading day immediately following our delivery of an
advance notice to the Selling Shareholder.
The Selling Shareholder may
sell the Ordinary Shares included in this prospectus in a number of different ways and at varying prices. We provide more information
about how the Selling Shareholder may sell the shares in the section entitled “Plan of Distribution.” The Selling Shareholder
is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act.
The Selling Shareholder will
pay all brokerage fees and commissions and similar expenses in connection with the offer and sale of the Ordinary Shares by the Selling
Shareholder pursuant to this prospectus. We will pay the expenses (except brokerage fees and commissions and similar expenses) incurred
to register under the Securities Act the offer and sale of the Ordinary Shares included in this prospectus by the Selling Shareholder.
See “Plan of Distribution.”
Our Ordinary Shares are listed on the Nasdaq Capital Market, or
Nasdaq, under the symbol “WLDS”. On September 20, 2024, the last reported sale price of our Ordinary Shares on Nasdaq was
$0.276 per share.
Investing in our securities
involves a high degree of risk. See “Risk Factors” beginning on page 4 of this prospectus.
Neither the Securities
and Exchange Commission, or the SEC, nor any state or other foreign securities commission has approved nor disapproved these securities
or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is ,
2024
TABLE OF CONTENTS
You should rely only on
the information contained in this prospectus. We have not, and the selling shareholder has not, authorized anyone to provide you with
any information other than that contained in this prospectus. We and the selling shareholder take no responsibility for and can provide
no assurance as to the reliability of, any other information that others may give you. This prospectus may only be used where it is legal
to offer and sell our securities. The information in this prospectus is accurate only as of the date of this prospectus, regardless of
the time of delivery of this prospectus or any sale of our securities. Our business, financial condition, results of operations and prospects
may have changed since that date. We are not, and the selling shareholder not, making an offer of these securities in any jurisdiction
where the offer is not permitted.
For investors outside of the
United States: Neither we nor the selling shareholder have done anything that would permit this offering or possession or distribution
of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to
inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus.
In this prospectus, “we,”
“us,” “our,” the “Company” and “Wearable Devices” refer to Wearable Devices Ltd. “Mudra”
is a registered trademark of Wearable Devices Ltd.
All trademarks or trade names
referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in
this prospectus are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that
their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or
display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any
other companies.
Our reporting currency and
functional currency is the U.S. dollar. Unless otherwise expressly stated or the context otherwise requires, references in this prospectus
to “NIS” are to New Israeli Shekels, and references to “dollars” or “$” mean U.S. dollars.
This prospectus includes or
incorporates by reference statistical, market and industry data and forecasts which we obtained from publicly available information and
independent industry publications and reports that we believe to be reliable sources. These publicly available industry publications and
reports generally state that they obtain their information from sources that they believe to be reliable, but they do not guarantee the
accuracy or completeness of the information.
We report in accordance with
generally accepted accounting principles in the United States, or U.S. GAAP.
PROSPECTUS
SUMMARY
This summary highlights
information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing
in our securities. Before you decide to invest in our securities, you should read the entire prospectus carefully, including the “Risk
Factors” section and the financial statements and related notes thereto and the other information incorporated by reference herein.
Our Company
We are a growth company developing a non-invasive neural input
interface in the form of a wearable wristband for controlling digital devices using subtle finger gestures and hand movements. Since our
technology was introduced to the market in 2014, we have been working with both B2B and B2C customers as part of our push-pull strategy.
We are now in the transition phase from research and development to commercialization of our technology into B2B products. At the same
time, starting in December 2023, we have commenced shipment of the “Mudra Band”, our first B2C consumer product, and aftermarket
accessory band for Apple Watch that enables gesture control across Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and
iPad, inter alia. In September 2024, we launched the Mudra Link, a universal gesture control wearable wristband. The Mudra Link is open
for pre-orders and is expected to ship in the first quarter of 2025.
Our
company’s vision is to create a world in which the user’s hand becomes a universal input device for touchlessly interacting
with technology. We believe that our technology is setting the standard input interface for the Metaverse. We intend to transform interaction
and control of digital devices to be as natural and intuitive as real-life experiences. We imagine a future in which humans can share
skills, thoughts, emotions, and movements with each other and with computers, using wearable interfaces and devices. We believe that neural-based
interfaces will become as ubiquitous to interact with wearable computing and digital devices in the near future as the touchscreen is
a universal input method for smartphones.
Combining
our own proprietary sensors and AI algorithms into a stylish wristband, our Mudra platform enables users to control digital devices through
subtle finger movements and hand gestures, without physical touch or contact. These digital devices include consumer electronics, smart
watches, smartphones, augmented reality, or AR, glasses, virtual reality, or VR, headsets, televisions, personal computers and laptop
computers, drones, robots, etc.
Mudra Development Kit, originally named Mudra Inspire, our B2B
development kit product, started selling to B2B customers in 2018 as the first point of business engagement and contributed to our early-stage
revenues. Our early-stage revenues are composed of sales of our Mudra Inspire and from pilot transactions with several B2B customers.
Towards the end of 2023, we commenced the shipments of the “Mudra Band”, our first B2C consumer product and since the fourth
quarter of 2023 we have shipped over one thousand Mudra Bands. In September 2024, we launched the Mudra Link, a universal gesture control
wearable wristband. The Mudra Link is open for pre-orders and is expected to ship in the first quarter of 2025.
In 2023 and 2022, we had revenues of $82 thousand and $45 thousand, respectively, and comprehensive and net loss of $7.8 million and $6.5
million, respectively. As of June 30, 2024 and June 30, 2023, we had revenues of $394 thousand and $12 thousand, respectively, and comprehensive
and net loss of $4.2 million and $3.9 million, respectively.
Over 100 companies have purchased our Mudra Inspire development
kit, 30 of which are multinational technology companies. These companies are exploring various input and control use-cases for their products,
ranging over multiple countries and industry sectors, including consumer electronics manufacturers, consumer electronics brands, electronic
components manufacturers, IT services and software development companies, industrial companies, and utility providers. Our objective with
these companies is to commercialize the Mudra technology by licensing it for integration in the hardware and software of these companies’
products and services. We estimate that there will be a three-to-five-year period from the time we are first introduced to a customer
to signing a licensing agreement. As of September 20, 2024, we have not signed a license agreement with any of these companies.
In
addition to consumer electronics, we have recently expanded our brand to include neurotech and brain-computer interface sensors, with
additional verticals that include Industry 4.0 – a new phase in the Industrial Revolution that focuses on interconnectivity, automation,
machine learning, and real-time data, digital health, sport analytics, and more.
The core of our platform is Mudra,
which means “gesture” in Sanskrit. Mudra, our surface nerve conductance, or SNC, technology and wristband tracks neural signals
on the user’s wrist skin surface, which our algorithms decipher to predict as gestures made by finger and hand movements. The interface
binds each gesture with a specific digital function, allowing users to input commands without physical touch or contact. Mudra gestures
are natural to perform, and gestures can be tailored per a user’s intent, desired function, and the controlled digital device. Mudra
can detect multiple gesture types, including hand movements, finger movements, and fingertip pressure gradations. In addition to the control
use-case, our Mudra technology and SNC sensor can be utilized in multiple monitoring use-cases where we can monitor neural and hand movements
for digital health purposes, sport analytics performance, and Industry 4.0 solutions.
Standby Equity Purchase Agreement with YA
On June 6, 2024, we entered into the SEPA with YA. Pursuant to
the SEPA, we will be able to sell up to $10.0 million of our Ordinary Shares, at our sole option, any time during the three-year period
following the execution date of the SEPA. Of the Commitment Amount, to date we have sold 3,715,602 Ordinary Shares for aggregate gross
proceeds of $1.7 million. Pursuant to the terms of the SEPA, any Ordinary Shares sold to YA will be priced at 97% of the market price,
which is defined as the lowest daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing
on the trading day immediately following our delivery of an advance notice to YA, or the Advance Price. Any sale of Ordinary Shares pursuant
to the SEPA is subject to certain limitations, including that YA is not permitted to purchase any Ordinary Shares that would result in
it owning more than 4.99% of our Ordinary Shares.
Subject to certain conditions precedent as described in the SEPA,
we may request Pre-Paid Advances in an amount up to $3.0 million. Each Pre-Paid Advance will be evidenced by a Promissory Note. Each Promissory
Note will fully mature 12-months following its issuance and shall accrue interest on the outstanding principal balance thereon at a rate
of 6% per annum, increasing to 18% per annum upon an Event of Default (as defined in the Promissory Note). Beginning 60 days after the
issuance of a Promissory Note, we shall pay to YA a monthly installment payment of 10% of the original principal amount of the Promissory
Note and accrued interest, payable in cash or by submitting an Advance Notice, where YA will offset the amount due to be paid to us under
such notice against an equal amount of the monthly installment amount, at our option. If we elect to pay in cash, the installment amount
shall also include a payment premium in the amount of 5% of the principal amount of the installment payment. The Promissory Note contains
our customary representations and warranties and Events of Default. Each Promissory Note will be convertible at a conversion price equal
to $0.70 per Ordinary Share and contains customary adjustments in the event of stock dividends, stock splits, reorganizations or similar
events affecting our Ordinary Shares and the conversion price. Each Promissory Note will also contain anti-dilution provisions that provide
that if we issue Ordinary Shares, or securities convertible into or exercisable or exchange for, shares of Ordinary Shares at a price
per share that is less than the conversion price then in effect, then the conversion price of the Promissory Note upon each such issuance
will be adjusted to the price equal to the consideration per share paid for such Ordinary Share or other securities. As of the date of
this prospectus, we have requested and received a Pre-Paid Advance in the amount of $2.0 million on June 6, 2024, which was evidenced
by a Promissory Note issued on the same date. As of the date of this prospectus, we have repaid $400 thousand of the principal amount
of such Promissory Note.
We are not obligated to utilize
any of the $10.0 million available under the SEPA and there are no minimum commitments or minimum use penalties. The total amount of funds
that ultimately can be raised under the SEPA over the three-year term will depend on the market price for the Ordinary Shares and the
number of Ordinary Shares actually sold. The SEPA does not impose any restrictions on our operating activities. During the term of the
SEPA, YA, and its affiliates, are prohibited from engaging in any short selling or hedging transactions related to the Ordinary Shares.
In addition, we also agreed to pay YA the Commitment Fee, equal
to $100,000, or 1.0% of the aggregate amount available to be sold under the SEPA, as consideration for its irrevocable commitment to purchase
our Ordinary Shares under the SEPA. The Commitment Fee will be issued in two tranches, with 50% of the Commitment Fee due on the date
that is 90 days from the date of the SEPA in an amount of Ordinary Shares equal to 50% of the Commitment Fee divided by the average of
the daily VWAP (as defined in the SEPA) of our Ordinary Shares during the three trading days immediately prior to such first payment date
and the remainder of the Commitment Fee due 180 days from the date of the SEPA in an amount of Ordinary Shares equal to 50% of the Commitment
Fee divided by the average of the daily VWAP (as defined in the SEPA) of our Ordinary Shares during the three trading days immediately
prior to such second payment date. On September 4, 2024, we and YA agreed to postpone the issuance of the first tranche of the Commitment
Fee and to issue the full 1.0% of the Commitment Fee to YA on the date that is 180 days from the date of the SEPA. The Commitment Fee
will be paid by the issuance to YA of such number of Ordinary Shares that is equal to the balance of the Commitment Fee divided by the
average of the daily VWAP of the Ordinary Shares during the three trading days immediately prior to the payment date. We have also agreed
to pay to YA a structuring fee in the amount of $10,000.
Pursuant to the SEPA, we were required to register resales of
the Ordinary Shares eligible to be sold pursuant to the SEPA and Commitment Fee, collectively referred to as the Registrable Shares. We
agreed to file this registration statement, which was originally declared effective by the SEC on June 24, 2024, and shall not have the
ability to request any advances under the SEPA until the post-effective amendment to this registration statement, of which this prospectus
forms a part, is declared effective.
Corporate Information
We are an Israeli corporation
based in Yokne’am Illit, Israel and were incorporated in Israel in 2014 under the name Wearable Devices Ltd. Our principal executive
offices are located at 5 Ha-Tnufa St., Yokne’am Illit, 2066736 Israel. Our telephone number in Israel is 972.4.6185670. Our website
address is www.wearabledevices.co.il. The information contained on, or that can be accessed through, our website is not part of this prospectus.
We have included our website address in this prospectus solely as an inactive textual reference.
THE
OFFERING
Ordinary Shares currently issued and outstanding |
|
24,103,030 Ordinary Shares |
|
|
|
Ordinary Shares offered by the Selling Shareholder |
|
Up to 24,574,209 Ordinary Shares that we may sell and issue to YA under this SEPA from time
to time (including 3,715,602 Ordinary Shares already sold as of the date of this prospectus). |
|
|
|
Ordinary Shares to be outstanding after this offering |
|
44,961,637 Ordinary Shares, assuming the sale and issuance of a total 24,574,209 Ordinary
Shares to YA pursuant to the SEPA, including 3,715,602 Ordinary Shares already sold as of the date of this prospectus (assuming actual
proceeds of approximately $1.7 million for Ordinary Shares already sold and the remaining Ordinary Shares at an assumed price per share
of $0.276, which is the last reported sales price of our Ordinary Shares on Nasdaq on September 20, 2024). |
|
|
|
Use of proceeds |
|
We will not receive any proceeds from the sale of the Ordinary Shares included in this prospectus by the Selling Shareholder. We may receive up to $10.0 million aggregate gross proceeds under the SEPA from sales of the Ordinary Shares that we elect to make to YA pursuant to the SEPA, if any, from time to time in our sole discretion, although the actual amount of proceeds that we may receive cannot be determined at this time and will depend on the number of shares we sell under the SEPA and market prices at the times of such sales. In connection with the SEPA, we may request Pre-Paid Advances of the Commitment Amount in an amount up to $3.0 million. Any proceeds that we receive from sales of our Ordinary Shares to YA or Pre-Paid Advances under the SEPA will be used for working capital and general corporate purposes and to repay installment amounts due under any Pre-Paid Advances. See “Use of Proceeds.” |
|
|
|
Risk factors |
|
You should read the “Risk Factors” section
beginning on page 4 of this prospectus and in the documents incorporated by reference in this prospectus for a discussion of factors
to consider before deciding to purchase our securities. |
|
|
|
Nasdaq symbol |
|
“WLDS” for the Ordinary Shares and “WLDSW” for the warrants issued in our initial public offering, or the IPO Warrants. |
The number of Ordinary Shares to be outstanding immediately after
this offering as shown above is based on 24,103,030 Ordinary Shares outstanding as of September 20, 2024 and assumes that all of the Ordinary
Shares offered hereby are sold and no Pre-Funded Warrants were sold. This number excludes:
|
● |
1,919,189 Ordinary Shares issuable upon the exercise of outstanding options allocated or granted to directors, employees and consultants under our 2015 Share Option Plan, or the 2015 Plan, at a weighted average exercise price of $0.70, of which 1,381,342 were vested as of September 20, 2024; |
|
|
|
|
● |
22,205 Ordinary Shares issuable upon the exercise of warrants issued to a consultant, at an exercise price of $2.25, which are all vested as of September 20, 2024, and an additional 23,640 Ordinary Shares issuable upon the exercise of warrants issued to an advisor, at an exercise price of $4.23 per Ordinary Share; |
|
● |
896,637 Ordinary Shares reserved for future issuance under the 2015 Plan; |
|
● |
7,860,861 Ordinary Shares issuable upon the exercise of 7,860,861 IPO Warrants issued in our initial public offering, or the IPO, and warrants to purchase up to 187,500 Ordinary Shares, issued to the underwriter in the IPO, or the Underwriter’s Warrants; |
|
|
|
|
● |
5,000,000 Ordinary Shares reserved for future issuance under our 2024 Employee Stock Purchase Plan, or the 2024 Purchase Plan; and |
|
|
|
|
● |
4,570,606 Ordinary Shares reserved for future issuance under our 2024 Global Equity Incentive Plan, or the 2024 Plan. |
RISK
FACTORS
An investment in our securities
involves a high degree of risk. You should carefully consider the risks and uncertainties described below and those described under the
section captioned “Risk Factors” contained in our Annual Report on Form 20-F for the year ended December 31, 2023 and all
other information contained or incorporated by reference into this prospectus and the documents incorporated by reference into this prospectus
before making an investment in our securities. Our business, financial condition or results of operations could be materially and adversely
affected if any of these risks occurs and, as a result, the market price of our securities could decline and you could lose all or part
of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See “Cautionary
Statement Regarding Forward-Looking Statements.” Our actual results could differ materially and adversely from those anticipated
in these forward-looking statements as a result of certain factors.
Risks Related to the Offering
It is not possible to predict the actual
number of shares we will sell under the SEPA to the Selling Shareholder, or the actual gross proceeds resulting from those sales.
On June 6, 2024, we entered into the SEPA with YA, pursuant to
which YA has committed to purchase up to $10.0 million of our Ordinary Shares, subject to certain limitations and conditions set forth
in the SEPA. Of the Commitment Amount, to date we have sold 3,715,602 Ordinary Shares for aggregate gross proceeds of $1.7 million. The
Ordinary Shares that may be issued under the SEPA may be sold by us to YA at our discretion from time to time over an approximately 36-month
period commencing on the date of the SEPA.
We generally have the right
to control the timing and amount of any sales of our Ordinary Shares to YA under the SEPA. Sales of our Ordinary Shares, if any, to YA
under the SEPA will depend upon market conditions and other factors. We may ultimately decide to sell to YA all, some or none of the Ordinary
Shares that may be available for us to sell to YA pursuant to the SEPA.
Because the purchase price
per share to be paid by YA for the Ordinary Shares that we may elect to sell to YA under the SEPA, if any, will fluctuate based on the
market prices of Ordinary Shares during the applicable purchase valuation period for each purchase made pursuant to the SEPA, if any,
it is not possible for us to predict, as of the date of this prospectus and prior to any such sales, the number of Ordinary Shares that
we will sell to YA under the SEPA, the purchase price per share that YA will pay for shares purchased from us under the SEPA, or the aggregate
gross proceeds that we will receive from those purchases by YA under the SEPA, if any.
The SEPA provides that we
may sell up to an aggregate of $10.0 million of our Ordinary Shares to YA, in our sole discretion, from time to time from and after the
date of, and pursuant to, the SEPA. Even if we elect to sell to YA all of the Ordinary Shares being registered for resale under this prospectus,
depending on the market prices of our Ordinary Shares at the time of such sales, the actual gross proceeds from the sale of all such shares
may be substantially less than the $10.0 million total commitment under the SEPA, which could materially adversely affect our liquidity.
If we desire to issue and
sell to YA under the SEPA more than the 24,547,209 Ordinary Shares being registered for resale under this prospectus, we would need to
file with the SEC one or more additional registration statements to register under the Securities Act the resale by YA of any such additional
Ordinary Shares and the SEC would have to declare such registration statement or statements effective before we could sell additional
shares.
Any issuance and sale by us
under the SEPA of a substantial number of Ordinary Shares in addition to the Ordinary Shares being registered for resale by YA under this
prospectus could cause additional substantial dilution to our shareholders. The number of Ordinary Shares ultimately offered for sale
by YA is dependent upon the number of Ordinary Shares, if any, we ultimately sell to YA under the SEPA.
Further, the resale by YA
of a significant number of shares registered for resale in this offering at any given time, or the perception that these sales may occur,
could cause the market price of our Ordinary Shares to decline and to be highly volatile.
Investors who buy shares at different times
will likely pay different prices.
Pursuant to the SEPA, we will
have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold to YA. If and when we do elect to sell
Ordinary Shares to YA pursuant to the SEPA, YA may resell all, some or none of such shares at any time or from time to time in its discretion
and at different prices. As a result, investors who purchase shares from YA in this offering at different times will likely pay different
prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes
in their investment results. Investors may experience a decline in the value of the shares they purchase from YA in this offering as a
result of future sales made by us to YA at prices lower than the prices such investors paid for their shares in this offering.
We may require additional financing to sustain
our operations and without it we will not be able to continue operations.
The
extent to which we rely on YA as a source of funding will depend on a number of factors, including the prevailing market price of our
Ordinary Shares, our ability to meet the conditions necessary to deliver advance notices under the SEPA and the extent to which we are
able to secure funding from other sources. Regardless of the amount of funds we ultimately raise under the SEPA, if any, we expect to
continue to seek other sources of funding. Even if we were to sell to YA the total commitment of $10.0 million, of which to date we have
sold 3,715,602 Ordinary Shares for aggregate gross proceeds of $1.7 million under the SEPA, we will still need additional capital to
fully implement our business plan.
Future sales and issuances of our Ordinary
Shares or other securities might result in significant dilution and could cause the price of our Ordinary Shares to decline.
To raise capital, we may sell
Ordinary Shares, convertible securities or other equity securities in one or more transactions other than those contemplated by the SEPA,
at prices and in a manner we determine from time to time. We may sell shares or other securities in any other offering at a price per
share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in
the future could have rights superior to existing stockholders. The price per share at which we sell additional Ordinary Shares, or securities
convertible or exchangeable into Ordinary Shares, in future transactions may be higher or lower than the price per share paid by investors
in this offering. Any sales of additional shares will dilute our stockholders.
Sales of a substantial number
of Ordinary Shares in the public market or the perception that these sales might occur could depress the market price of our Ordinary
Shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect
that sales may have on the prevailing market price of our Ordinary Shares. In addition, the sale of substantial numbers of our Ordinary
Shares could adversely impact their price.
Management will have broad discretion as
to the use of the proceeds from the SEPA or any potential Pre-Paid Advance and uses may not improve our financial condition or market
value.
Because we have not designated
the amount of net proceeds or potential Pre-Paid Advance from the SEPA to be used for any particular purpose, our management will have
broad discretion as to the application of such proceeds. Our management may use the proceeds for working capital and general corporate
purposes that may not improve our financial condition or advance our business objectives.
Risks Related to Operations in Israel
We conduct our operations
in Israel. Conditions in Israel, including conditions affected by the recent attack by Hamas and other terrorist organizations and Israel’s
war against them, may affect our operations.
Our offices are located in
Yokne’am Illit, Israel, thus, political, economic, and military conditions in Israel may directly affect our business. On October
7, 2023, Hamas terrorists infiltrated Israel’s southern border from the Gaza Strip and conducted a series of attacks on civilian
and military targets. Hamas also launched extensive rocket attacks on the Israeli population and industrial centers located along Israel’s
border with the Gaza Strip and in other areas within the State of Israel. Following the attack, Israel’s security cabinet declared
war against Hamas and the Israeli military began to call-up reservists for active duty. At the same time, and because of the declaration
of war against Hamas, the clash between Israel and Hezbollah along Israel’s northern border with Lebanon and southern border with
the Houthi movement in Yemen have escalated and there is a possibility that either or both will turn into a greater regional conflict
in the future. In addition, Iran recently launched a direct attack on Israel involving hundreds of drones and missiles, and has threatened
to continue to attack Israel and is widely believed to be developing nuclear weapons. Iran is also believed to have a strong influence
among extremist groups in the region, such as Hamas in Gaza, Hezbollah in Lebanon, the Houthi movement in Yemen and various rebel militia
groups in Syria.
As
of today, these events have had no material impact on the Company’s operations. According to the recent guidelines of the Israeli
government, the Company’s offices are open and functioning as usual. However, if the war escalates and expands to the Northern border
with Lebanon, Iran or Yemen, the Israeli government potentially will impose additional restrictions on movement and travel, and our management
and employees’ ability to effectively perform their daily tasks might be temporarily disrupted, which may result in delays in some
of our projects.
The
Company currently has the supply of materials needed for its regular operations. While there may be some possible delays in supply, those
are currently not anticipated to be material to the Company’s operations. However, if the war continues for a significant amount
of time, this situation may change.
Any hostilities involving Israel, terrorist activities, political
instability or violence in the region, or the interruption or curtailment of trade or transport among Israel and its trading partners
could make it more difficult for us to raise capital, if needed in the future, and adversely affect our operations and results of operations
and the market price of our Ordinary Shares. Moreover, we cannot predict how this war will ultimately affect Israel’s economy in
general, which may involve a downgrade in Israel’s credit rating by rating agencies (such as the recent downgrade by Moody’s
of its credit rating of Israel from A1 to A2, as well as the downgrade of its outlook rating from “stable” to “negative”
and the S&P Global lowered its long-term credit rating from AA- to A+, as well as a downgrade of its short-term credit ratings from
A-1+ to A-1, with an outlook on the long-term ratings “negative”, and recently Fitch Ratings Inc. lowered Israel’s credit
rating from A+ to A, with an outlook rating of “negative”).
Our
commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle
East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by
terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or, if maintained, will be sufficient
to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business,
financial condition, and results of operations.
Further, many Israeli citizens are obligated to perform several
days, and in some cases, more, of annual military reserve duty each year until they reach the age of 40 (or older for certain reservists)
and, in the event of a military conflict, may be called to active duty. In response to the series of attacks on civilian and military
targets in October 2023, there have been significant call-ups of military reservists. As of September 20, 2024, none of the Company’s
employees is in military reserve service. However, if the number of reservists in our Company increases and becomes significant, our operations
could be disrupted by such call-ups.
Any
armed conflicts, terrorist activities or political instability in the region could adversely affect business conditions, could harm our
results of operations and the market price of our Ordinary Shares, and could make it more difficult for us to raise capital. Parties with
whom we do business may sometimes decline to travel to Israel during periods of heightened unrest or tension, forcing us to make alternative
arrangements when necessary, in order to meet our business partners face to face.
The
intensity and duration of Israel’s current war against Hamas is difficult to predict at this stage, as are such war’s economic
implications on the Company’s business and operations and on Israel’s economy in general. However, if the war extends for
a long period of time or expands to other fronts, such as Lebanon, Syria and the West Bank, our operations may be harmed.
It
is currently not possible to predict the duration or severity of the ongoing conflict or its effects on our business, operations and financial
condition. The ongoing conflict is rapidly evolving and developing, and could disrupt our business and operations, and adversely affect
our ability to raise additional funds or sell our securities, among other impacts.
CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS
Some of the statements made
under “Prospectus Summary,” “Risk Factors,” “Use of Proceeds,” and elsewhere in this prospectus, constitute
forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,”
“should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,”
“predicts,” “potential” “intends” or “continue,” or the negative of these terms or other
comparable terminology.
These forward-looking statements
may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections
of results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development,
completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or
developments that we intend, expect, project, believe or anticipate will or may occur in the future.
Forward-looking statements
are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on
assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions,
expected future developments and other factors they believe to be appropriate.
Important factors that could
cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements
include, among other things:
|
● |
our financial statements for the six months ended June 30, 2024, contained an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all; |
|
● |
SNC becoming the industry standard input method for wearable computing and consumer electronics; |
|
● |
our ability to maintain and expand our existing customer base; |
|
● |
our ability to maintain and expand compatibility of our devices with a broad range of mobile devices and operating systems; |
|
● |
timing of the shipment to early-booking orders of our Mudra Band; |
|
● |
our ability to maintain our business models; |
|
● |
our ability to correctly predict the market growth; |
|
● |
our ability to remediate material weaknesses in our internal control over financial reporting; |
|
● |
our ability to retain our founders; |
|
● |
our ability to maintain, protect, and enhance our intellectual property; |
|
● |
our ability to raise capital through the issuance of additional securities; |
|
● |
the impact of competition and new technologies; |
|
● |
general market, political and economic conditions in the countries in which we operate; |
|
● |
projected capital expenditures and liquidity; |
|
● |
changes in our strategy; and |
These statements are only
current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s
actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking
statements. We discuss many of these risks in this prospectus in greater detail under the heading “Risk Factors” and elsewhere
in this prospectus. You should not rely upon forward-looking statements as predictions of future events.
Although we believe that the
expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance,
or achievements. Except as required by law, we are under no duty to update or revise any of the forward-looking statements, whether as
a result of new information, future events or otherwise, after the date of this prospectus.
USE
OF PROCEEDS
This
prospectus relates to our Ordinary Shares that may be offered and sold from time to time by YA, the Selling Shareholder. All of the Ordinary
Shares offered by the Selling Shareholder pursuant to this prospectus will be sold by the Selling Shareholder for its own account. We
will not receive any of the proceeds from these sales.
We
may receive up to $10.0 million aggregate gross proceeds under the SEPA from any sales we make to YA pursuant to the SEPA. To date, we
have sold 3,715,602 of Ordinary Shares, pursuant to the SEPA for aggregate gross proceeds of $1.7 million. However, we are unable to
estimate the actual amount of proceeds that we may receive, as it will depend on the number of shares that we choose to sell, our ability
to meet the conditions to purchases set forth in SEPA, market conditions and the price of our Ordinary Shares, among other factors.
We
expect to use any proceeds that we receive under the SEPA for working capital and general corporate purposes, and to pay the monthly
installments on any Pre-Paid Advance. As of the date of this prospectus, we cannot specify with certainty all of the particular uses,
and the respective amounts we may allocate to those uses, for any net proceeds we receive. Accordingly, we will retain broad discretion
over the use of these proceeds.
DIVIDEND
POLICY
We
have never declared or paid any cash dividends on our Ordinary Shares and do not anticipate paying any cash dividends in the foreseeable
future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing
conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects
and other factors our board of directors may deem relevant. Under the Companies Law, the repurchase of shares is considered a dividend
distribution.
The
Companies Law imposes further restrictions on our ability to declare and pay dividends. Under the Companies Law, we may declare and pay
dividends only if, upon the determination of our board of directors, there is no reasonable concern that the distribution will prevent
us from being able to meet the terms of our existing and foreseeable obligations as they become due, or the Solvency Criteria. Under
the Companies Law, the distribution amount is further limited to the greater of retained earnings or earnings generated over the two
most recent years legally available for distribution according to our then last reviewed or audited financial statements, provided that
the end of the period to which the financial statements relate is not more than six months prior to the date of distribution. In the
event that we do not meet such earnings criteria, we may seek the approval of a court in order to distribute a dividend. The court may
approve our request if it is convinced that there is no reasonable concern that the payment of a dividend will prevent us from satisfying
our existing and foreseeable obligations as they become due.
However,
pursuant to regulations promulgated under the Companies Law, an Israeli company whose shares are listed outside of Israel is permitted
to perform a distribution by way of repurchasing its own shares, even if the earnings criteria are not met, without the need for court
approval. The exemption is subject to certain conditions, including, among others: (i) the distribution meets the Solvency Criteria;
and (ii) no rejection was filed by any of the company’s creditors to the court. If any creditor objects to the distribution, the
company will be required to obtain the court’s approval for the distribution.
Payment
of dividends may be subject to Israeli withholding taxes (see “Taxation” included in our Annual Report on Form 20-F
for the year ended December 31, 2023 for additional information).
CAPITALIZATION
The
following table sets forth our cash and cash equivalents and our capitalization as of June 30, 2024:
|
● |
on an actual basis; |
|
|
|
|
● |
on a pro forma basis to
give effect to the issuance of 3,215,602 Ordinary Shares under the SEPA between July 1, 2024 and September 20, 2024, for aggregate
gross proceeds of $1.4 million, as if such issuances had occurred as of June 30, 2024; and |
| ● | on
an as adjusted basis to give effect to the issuance of additional 20,858,607 Ordinary Shares
under the SEPA based on 24,574,209 Ordinary Shares under offering, less 3,715,602 Ordinary
Shares already sold until the date of this prospectus, at an assumed public offering price
of $0.276 per Ordinary Share, which is the last reported sales price on Nasdaq of our Ordinary
Shares on September 20, 2024, and after deducting estimated offering expenses, as if the
sale of the Ordinary Shares had occurred on June 30, 2024. |
You
should read this table in conjunction with our Unaudited Interim Financial Statements as of June 30, 2024 and “Management’s
Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2024” attached as exhibits
99.1 and 99.2, respectively, to our Report of Foreign Private Issuer on Form 6-K, or a Form 6-K, filed on September 23, 2024 and incorporated
by reference herein.
| |
As
of June 30, 2024 | |
U.S.
dollars in thousands | |
Actual* | | |
Pro
Forma* | | |
Pro
Forma As Adjusted* | |
Cash | |
| 3,103 | | |
| 4,517 | | |
| 10,274 | |
Long term debt | |
| 144 | | |
| 144 | | |
| 144 | |
Shareholders’ equity: | |
| | | |
| | | |
| | |
Share capital | |
| 58 | | |
| 68 | | |
| 130 | |
Additional paid in capital | |
| 27,070 | | |
| 28,474 | | |
| 34,169 | |
Accumulated losses | |
| (25,433 | ) | |
| (25,433 | ) | |
| (25,433 | ) |
Total shareholders’
equity | |
| 1,695 | | |
| 3,109 | | |
| 8,866 | |
Total capitalization | |
| 1,839 | | |
| 3,253 | | |
| 9,010 | |
The
table above is based on 20,887,428 Ordinary Shares outstanding as of June 30, 2024. This number excludes:
| ● | 1,744,189
Ordinary Shares issuable upon the exercise of outstanding options allocated or granted to
directors, employees and consultants under the 2015 Plan, at a weighted average exercise
price of $0.73, of which 1,381,342 were vested as of September 20, 2024; |
| ● | 22,205
Ordinary Shares issuable upon the exercise of warrants issued to a consultant at an exercise
price of $2.25, which are all vested as of September 20, 2024, and additional 23,640 Ordinary
Shares issuable upon the exercise of warrants issued to an advisor, at an exercise price
of $4.23 per Ordinary Share; |
| ● | 1,071,637
Ordinary Shares reserved for future issuance under the 2015 Plan; |
| ● | 7,860,861
Ordinary Shares issuable upon exercise of 7,860,861 IPO Warrants issued in the IPO and Underwriter’s
Warrants to purchase up to 187,500 Ordinary Shares; |
| ● | 5,000,000
Ordinary Shares reserved for future issuance under the 2024 Purchase Plan; and |
| ● | 4,570,606
Ordinary Shares reserved for future issuance under the 2024 Plan. |
DESCRIPTION
OF SHARE CAPITAL
The
following description of the share capital of Wearable Devices Ltd., or the Company, and the provisions of our articles of association and
Israeli law are summaries, do not purport to be complete and is qualified in its entirety by reference to our articles of
association, Israeli law and any other documents referenced.
Type
and class of securities
Ordinary
Shares
As
of September 20, 2024, our authorized share capital consists of 50,000,000 Ordinary Shares, NIS 0.01 par value per share, of which 24,103,030
Ordinary Shares were issued and outstanding as of such date.
All
of our outstanding Ordinary Shares have been validly issued, fully paid and non-assessable. Our Ordinary Shares are not redeemable and
are not subject to any preemptive right.
Our
Ordinary Shares and previously issued warrants, or the IPO Warrants, have been listed on the Nasdaq Capital Market under the symbol “WLDS”
and “WLDSW,” respectively, since September 13, 2022.
Warrants
and Options
As
of September 20, 2024, we have issued and outstanding IPO Warrants to purchase an aggregate of 7,860,861 Ordinary Shares, with exercise
price of $2.00 per Ordinary Share. The warrants were issued as part of our IPO, and have been listed on the Nasdaq Capital Market under
the symbol “WLDSW” since September 13, 2022.
As
of September 20, 2024, we have 1,919,189 Ordinary Shares issuable upon the exercise of outstanding options allocated or granted to certain
employees, directors and consultants, under our 2015 Share Option Plan. An additional 896,637 Ordinary Shares are reserved for future
issuance under our 2015 Share Option Plan.
Articles
of Association
Directors
Our
board of directors shall direct our policy and shall supervise the performance of our Chief Executive Officer and his actions. Our board
of directors may exercise all powers that are not required under the Israeli Companies Law 5759-1999, or the Companies Law, or under
our articles of association to be exercised or taken by our shareholders.
Rights
Attached to Ordinary Shares
Our
Ordinary Shares shall confer upon the holders thereof:
|
● |
equal right to attend and
to vote at all of our general meetings, whether regular or special, with each Ordinary Share entitling the holder thereof, which
attend the meeting and participate at the voting, either in person or by a proxy or by a written ballot, to one vote; |
|
● |
equal right to participate
in distribution of dividends, if any, whether payable in cash or in bonus shares, in distribution of assets or in any other distribution,
on a per share pro rata basis; and |
|
● |
equal right to participate,
upon our dissolution, in the distribution of our assets legally available for distribution, on a per share pro rata basis. |
Election
of Directors
Pursuant
to our articles of association, our directors are elected and/or re-elected by the general meeting and, unless appointed for a shorter
term, serve in office until the third annual general meeting after the general meeting in which such director was appointed, in which
such later annual general meeting the directors will be brought for re-election or replacement.
In
each annual general meeting, the election or re-election of directors following the expiration of the term of office of the directors
of that class of directors will be for a term of office that expires on the third annual general meeting following such election or re-election,
such that each year the term of office of only one class of directors will expire, and all other directors whose service term lapsed
shall be deemed to have been re-elected for a term until the next annual general meeting. The director to be deemed and to be re-elected
is the director that served the longest period since its appointment or last re-election. If more than one director served the longest
time, the board of directors will decide which of such directors will be brought for re-election at the relevant general meeting.
Annual
and Special Meetings
Under
the Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year, at such time and place
which shall be determined by our board of directors, that must be no later than 15 months after the date of the previous annual general
meeting. All meetings other than the annual general meeting of shareholders are referred to as special general meetings. Our board of
directors may call special meetings whenever it sees fit and upon the request of: (a) any two of our directors or such number of directors
equal to one quarter of the directors then at office; and/or (b) one or more shareholders holding, in the aggregate, (i) 5% or more of
our outstanding issued shares and 1% of our outstanding voting power or (ii) 5% or more of our outstanding voting power, or the Non Exempted
Holding. However, under a new exemption applicable as of March 12, 2024, the board of directors of an Israeli company whose shares are
listed outside of Israel, shall convene a special meeting at the request of: (i) one or more shareholders holding at least ten percent
(10%) of the issued and outstanding share capital instead of five (5%) in the past, and at least one percent (1%) of the voting rights
in the company, or (ii) one or more shareholders holding at least ten percent (10%) of the voting rights in the company, unless the applicable
law incorporated in the country in which the Company is listed for trade, establishes a right to demand convening of such a meeting for
those holding less than ten percent (10%) of the voting rights in the company (in which case, the Non Exempted Holding shall apply).
Under
Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors
include a matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter
at the general meeting. Under new exemptions applicable as of March 12, 2024, one or more shareholders of an Israeli company whose shares
are listed outside of Israel, may request the company’s board of directors to include an appointment of a candidate for a position
on the board of directors or the termination of a board member, as an item on the agenda of a future general meeting (if the company
sees fit), provided that the shareholder holds at least 5% of the voting rights of the company (instead of 1% in the past).
Subject
to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general
meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and sixty days prior
to the date of the meeting. Resolutions regarding the following matters must be passed at a general meeting of our shareholders:
|
● |
amendments to our articles
of association; |
|
● |
the exercise of our board
of directors’ powers by a general meeting if our board of directors is unable to exercise its powers and the exercise of any
of its powers is required for our proper management; |
|
● |
appointment or termination
of our auditors; |
|
● |
appointment of directors,
including external directors (other than with respect to circumstances specified in our articles of association); |
|
● |
approval of acts and transactions
requiring general meeting approval pursuant to the provisions of the Companies Law (mainly certain related party transactions) and
any other applicable law; |
|
● |
increases or reductions
of our authorized share capital; and |
|
● |
a merger (as such term
is defined in the Companies Law). |
Notices
The
Companies Law require that a notice of any annual or special shareholders meeting be provided at least 21 days prior to the meeting,
and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or
interested or related parties, approval of the company’s general manager to serve as the chairman of the board of directors or
an approval of a merger, notice must be provided at least 35 days prior to the meeting.
Quorum
According
to our articles of association and as permitted under the Companies Law, the quorum required for our general meetings consists of at
least two shareholders present in person, by proxy, written ballot or voting by means of electronic voting system, who hold or represent
between them at least 25% of the total outstanding voting rights. If within half an hour of the time set forth for the general meeting
a quorum is not present, the general meeting shall stand adjourned the same day of the following week, at the same hour and in the same
place, or to such other date, time and place as prescribed in the notice to the shareholders and in such adjourned meeting, any number
of shareholders participating in the meeting shall constitute a quorum.
If
a special general meeting was summoned following the request of a shareholder, and within half an hour a legal quorum was not formed,
the meeting shall be canceled.
Adoption
of Resolutions
Our
articles of association provide that those resolutions amending provisions of the articles of association related to the staggered board
of directors and the composition of the board of directors, as well as a resolution to dismiss a director, will require an affirmative
vote of 70% of the voting power represented at a general meeting and voting thereon. Other than that, and unless otherwise required under
the Companies Law and our articles, all resolutions of the Company’s shareholders require a simple majority vote. A shareholder
may vote in a general meeting in person, by proxy, by a written ballot.
Changing
Rights Attached to Shares
Unless
otherwise provided by the terms of the shares and subject to any applicable law, any modification of rights attached to any class of
shares must be adopted by the holders of a majority of the shares of that class present a general meeting of the affected class or by
a written consent of all the shareholders of the affected class.
The
enlargement of an existing class of shares or the issuance of additional shares thereof, shall not be deemed to modify the rights attached
to the previously issued shares of such class or of any other class, unless otherwise provided by the terms of the shares.
Limitations
on the Right to Own
Securities in Our Company
There
are no limitations on the right to own our securities in our articles of association. In certain circumstances the IPO Warrants and the
Pre-Funded Warrants have restrictions upon the exercise of such warrants if such exercise would result in the holders thereof owning
more than 4.99% or 9.99% of our Ordinary Shares upon such exercise, as further described below.
Provisions
Restricting Change in
Control of Our Company
Our
articles of association provide for a staggered board of directors, which mechanism may delay, defer or prevent a change of control of
the Company’s board of directors. Other than that, there are no specific provisions of our articles of association that would have
an effect of delaying, deferring or preventing a change in control of the Company or that would operate only with respect to a merger,
acquisition or corporate restructuring involving us. However, as described below, certain provisions of the Companies Law may have such
effect.
The
Companies Law includes provisions that allow a merger transaction and requires that each company that is a party to the merger have the
transaction approved by its board of directors and, unless certain requirements described under the Companies Law are met, a vote of
the majority of shareholders, and, in the case of the target company, also a majority vote of each class of its shares. For purposes
of the shareholder vote of each party, unless a court rules otherwise, the merger will not be deemed approved if shares representing
a majority of the voting power present at the shareholders meeting and which are not held by the other party to the merger (or by any
person or group of persons acting in concert who holds 25% or more of the voting power or the right to appoint 25% or more of the directors
of the other party) vote against the merger. If, however, the merger involves a merger with a company’s own controlling shareholder
or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority
approval that governs all extraordinary transactions with controlling shareholders. Upon the request of a creditor of either party to
the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that as a result
of the merger the surviving company will be unable to satisfy the obligations of any of the parties to the merger, and may further give
instructions to secure the rights of creditors. If the transaction would have been approved by the shareholders of a merging company
but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still
approve the merger upon the petition of holders of at least 25% of the voting rights of a company. For such petition to be granted, the
court must find that the merger is fair and reasonable, taking into account the value of the parties to the merger and the consideration
offered to the shareholders. In addition, a merger may not be completed unless at least (1) 50 days have passed from the time that the
requisite proposals for approval of the merger were filed with the Israeli Registrar of Companies by each merging company and (2) 30
days have passed since the merger was approved by the shareholders of each merging company.
The
term “Special Majority” hereof will be defined as described in section 275(a)(3) of the Companies Law as:
|
● |
at least a majority of
the shares held by shareholders who are not controlling shareholders and do not have personal interest in the merger (excluding a
personal interest that did not result from the shareholder’s relationship with the controlling shareholder) have voted in favor
of the proposal (shares held by abstaining shareholders shall not be considered); or |
|
● |
the total number of shares
voted against the merger, does not exceed 2% of the aggregate voting rights of the company. |
The
Companies Law also provides that, subject to certain exceptions, an acquisition of shares in an Israeli public company must be made by
means of a “special” tender offer if as a result of the acquisition (1) the purchaser would become a holder of 25% or more
of the voting rights in the company, unless there is already another holder of at least 25% or more of the voting rights in the company
or (2) the purchaser would become a holder of 45% or more of the voting rights in the company, unless there is already a holder of more
than 45% of the voting rights in the company. These requirements do not apply if, in general, the acquisition (1) was made in a private
placement that received shareholders’ approval, subject to certain conditions, (2) was from a holder of 25% or more of the voting
rights in the company which resulted in the acquirer becoming a holder of 25% or more of the voting rights in the company, or (3) was
from a holder of more than 45% of the voting rights in the company which resulted in the acquirer becoming a holder of more than 45%
of the voting rights in the company. A “special” tender offer must be extended to all shareholders. In general, a “special”
tender offer may be consummated only if (1) at least 5% of the voting power attached to the company’s outstanding shares will be
acquired by the offeror and (2) the offer is accepted by a majority of the offerees who notified the company of their position in connection
with such offer (excluding the offeror, controlling shareholders, holders of 25% or more of the voting rights in the company or anyone
on their behalf, or any person having a personal interest in the acceptance of the tender offer). If a special tender offer is accepted,
then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity
may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target
company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an
offer or merger in the initial special tender offer. However, under a new exemption applicable
as of March 12, 2024, the aforesaid limitations do not apply for an Israeli company whose shares are listed outside of Israel, provided
that the applicable law as applicable to companies incorporated in the country which the company is listed for trade provide a restriction
on the acquisition of control of any proportion of the company or that the acquisition of control of any proportion requires the purchaser
to also offer a purchase offer to shareholders from among the public.
If,
as a result of an acquisition of shares, the acquirer will hold more than 90% of an Israeli company’s outstanding shares or of
certain class of shares, the acquisition must be made by means of a tender offer for all of the outstanding shares, or for all of the
outstanding shares of such class, as applicable. In general, if less than 5% of the outstanding shares, or of applicable class, are not
tendered in the tender offer and more than half of the offerees who have no personal interest in the offer tendered their shares, all
the shares that the acquirer offered to purchase will be transferred to it by operation of law. However, a tender offer will also be
accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company
or of the applicable class of shares. Any shareholders that was an offeree in such tender offer, whether such shareholder accepted the
tender offer or not, may request, by petition to an Israeli court, (i) appraisal rights in connection with a full tender offer, and (ii)
that the fair value should be paid as determined by the court, for a period of six months following the acceptance thereof. However,
the acquirer is entitled to stipulate, under certain conditions, that tendering shareholders will forfeit such appraisal rights.
However,
under a new exemption applicable as of March 12, 2024, the aforesaid limitations regarding a tender offer do not apply for an Israeli
company whose shares are listed outside of Israel, provided that if the applicable law as applicable to companies incorporated in the
country which the company is listed for trade, provide a restriction on the acquisition of control of any proportion of the company or
that the acquisition of control of any proportion requires the purchaser to also offer a purchase offer to shareholders from among the
public.
Lastly,
Israeli tax law treats some acquisitions, such as stock-for-stock exchanges between an Israeli company and a foreign company, less favorably
than U.S. tax laws. For example, Israeli tax law may, under certain circumstances, subject a shareholder who exchanges his Ordinary Shares
for shares in another corporation to taxation prior to the sale of the shares received in such stock-for-stock swap.
Changes
in Our Capital
The
general meeting may, by a simple majority vote of the shareholders attending the general meeting:
|
● |
increase our registered
share capital by the creation of new shares from the existing class or a new class, as determined by the general meeting; |
|
● |
cancel any registered share
capital which have not been taken or agreed to be taken by any person; |
|
● |
consolidate and divide
all or any of our share capital into shares of larger nominal value than our existing shares; |
|
● |
subdivide our existing
shares or any of them, our share capital or any of it, into shares of smaller nominal value than is fixed; and |
|
● |
reduce our share capital
and any fund reserved for capital redemption in any manner, and with and subject to any incident authorized, and consent required,
by the Companies Law. |
Exclusive
Forum
Our
articles of association provide that unless the Company consents in writing to the selection of an alternative forum, the federal district
courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising
under the Securities Act of 1933, as amended, or the Securities Act and that any person or entity purchasing or otherwise acquiring
any interest in any security of the Company, shall be deemed to have notice of and consented to this exclusive forum provision.
Staggered
Board
Our
articles of association provide for a split of the board of directors into three classes with staggered three-year terms. At each annual
general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors
of that class of directors will be for a term of office that expires on the third annual general meeting following such election or re-election,
such that each year the term of office of only one class of directors will expire. The director whom is to be retired and re-elected
shall be the director that served the longest period since its appointment or last re-election or, if more than one director served the
longest time, or if a director who is not to be re-elected agrees to be re-elected, the meeting of the board of directors which sets
the date and agenda for the annual general meeting (acting by a simple majority) will decide which of such directors will be brought
for re-election at the relevant general meeting.
SELLING
SHAREHOLDER
This
prospectus relates to the possible resale from time to time by YA of any or all of the Ordinary Shares that have been or may be issued
by us to YA under the SEPA. For additional information regarding the issuance of Ordinary Shares covered by this prospectus, see the
section titled “Prospectus Summary-Standby Equity Purchase Agreement with YA” above. Except for the transactions contemplated
by the SEPA, YA does not, and has not had, any material relationship with us.
The
table below presents information regarding the Selling Shareholder and the Ordinary Shares that it may offer from time to time under
this prospectus. This table is prepared based on information supplied to us by the Selling Shareholder. The number of shares in the column
“Maximum Number of Ordinary Shares to be Offered Pursuant to this Prospectus” represents all of the Ordinary Shares that
the Selling Shareholder may offer under this prospectus. The Selling Shareholder may sell some, all or none of its shares in this offering.
We do not know how long the Selling Shareholder will hold the shares before selling them, and we currently have no agreements, arrangements
or understandings with the Selling Shareholder regarding the sale of any of the shares.
Beneficial
ownership is determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes Ordinary Shares
with respect to which the Selling Shareholder has voting and investment power. The percentage of Ordinary Shares beneficially owned by
the Selling Shareholder prior to the offering shown in the table below is based on an aggregate of 24,103,030 of our Ordinary Shares
outstanding on September 20, 2024. The number of shares that may actually be sold by us under the SEPA may be fewer than the number of
shares being offered by this prospectus. The fourth column assumes the sale of all of the shares offered by the Selling Shareholder pursuant
to this prospectus.
| |
Number
of Shares of Ordinary Shares Owned Prior to Offering |
| |
Maximum
Number of Ordinary Shares to be Offered Pursuant to this Prospectus | | |
Number
of Ordinary Shares Owned After Offering | |
Name
of Selling Shareholder | |
Number(1) | |
Percent | | |
Number | | |
Number(2) | | |
Percent | |
YA II PN, LTD.(3) | |
0 | |
|
0 | % | |
| 24,574,209 | | |
| 0 | | |
| 0 | % |
(1) |
We have
excluded from the number of shares beneficially owned prior to the offering all of the shares that YA may be required to purchase
under the SEPA, because the issuance of such shares is solely at our discretion and is subject to conditions contained in the SEPA,
the satisfaction of which are entirely outside of YA’s control, including the registration statement that includes this prospectus
becoming and remaining effective. Additionally, the SEPA prohibits us from issuing and selling any Ordinary Shares to YA to the extent
that such shares, when aggregated with all other Ordinary Shares then beneficially owned by YA, would cause YA’s beneficial
ownership of our Ordinary Shares to exceed beneficial ownership of greater than 4.99% of the voting power or number of Ordinary Shares
outstanding. |
(2) |
Assumes
the sale of all Ordinary Shares being offered pursuant to this prospectus. Depending on the price per share at which we sell our
Ordinary Shares to YA pursuant to the SEPA, we may need to sell to YA under the SEPA more shares of our Ordinary Shares than are
offered under this prospectus in order to receive aggregate gross proceeds equal to the $10.0 million total commitment under the
SEPA. If we choose to do so and otherwise satisfy the conditions in the SEPA, we must first register for resale under the Securities
Act such additional shares. The number of shares ultimately offered for resale by YA is dependent upon the number of shares we sell
to YA under the SEPA. |
(3) |
YA II
PN, Ltd. is a fund managed by Yorkville Advisors Global, LP, or Yorkville LP. Yorkville Advisors Global II, LLC, or Yorkville LLC,
is the General Partner of Yorkville LP. All investment decisions for YA are made by Yorkville LLC’s President and Managing
Member, Mr. Mark Angelo. The business address of YA is 1012 Springfield Avenue, Mountainside, NJ 07092. |
plan
of distribution
On
June 6, 2024, we entered into the SEPA with YA. The SEPA provides that, upon the terms and subject to the conditions set forth therein,
YA is committed to purchase up to $10.0 million of our Ordinary Shares over an approximately 36-month commitment period. Of the Commitment
Amount, to date we have sold 3,715,602] Ordinary Shares for aggregate gross proceeds of $1.7 million. From time to time, and at our sole
discretion, we may present YA with advance notices to purchase our Ordinary Shares. The shares would be purchased pursuant to the SEPA
at 97% of the market price, which is defined as the lowest daily volume weighted average price of the Shares during the three consecutive
trading days commencing on the trading day immediately following our delivery of an advance notice to YA.
The
Ordinary Shares offered by this prospectus are being offered by the Selling Shareholder, YA. The Selling Shareholder is an “underwriter”
within the meaning of Section 2(a)(11) of the Securities Act. We have agreed in the SEPA to provide customary indemnification to YA.
It
is possible that our shares may be sold from time to time by YA in one or more of the following manners:
|
● |
ordinary
brokerage transactions and transactions in which the broker solicits purchasers; |
|
● |
transactions
involving cross or block trades; |
|
● |
to a broker-dealer as principal
and resale by the broker-dealer for its account; |
|
● |
“at the market”
into an existing market for our Ordinary Shares; |
|
● |
in privately negotiated
transactions; or |
|
● |
a combination of any such
methods of sale. |
YA
has agreed that, during the term of the SEPA, it shall not engage in any short sales or hedging transactions with respect to our Ordinary
Shares, provided that upon receipt of an advance notice, YA may sell shares that it is obligated to purchase under such advance notice
prior to taking possession of such shares.
We
have advised the Selling Shareholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain
exceptions, Regulation M precludes the Selling Shareholder, any affiliated purchasers, and any broker-dealer or other person who participates
in the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security that is the
subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order
to stabilize the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability
of the securities offered by this prospectus.
We
will pay the expenses incident to the registration under the Securities Act of the offer and sale of the Ordinary Shares covered by this
prospectus by the Selling Shareholder. We estimate that our total expenses for the offering will be approximately $100,000.
EXPENSES
Set
forth below is an itemization of the total expenses paid in connection with the offer and sale of the securities pursuant to this prospectus:
SEC registration fee | |
$ | 1,904.26 | |
Printer fees and expenses | |
$ | 5,000 | |
Legal fees and expenses | |
$ | 50,000 | |
Accounting and professional fees and expenses | |
$ | 10,000 | |
Miscellaneous | |
$ | 33,000 | |
Total | |
$ | 99,904.26 | |
LEGAL
MATTERS
Certain
legal matters concerning the SEPA were passed upon for us by Sullivan & Worcester LLP, New York, New York. Certain legal matters
with respect to the legality of the issuance of the securities offered by this prospectus and other legal matters concerning the SEPA
relating to Israeli law were passed upon for us by Sullivan & Worcester Tel Aviv (Har-Even & Co.), Tel Aviv, Israel.
EXPERTS
The
consolidated financial statements as of December 31, 2023 and 2022 and for each of the years in the three-year period ended December
31, 2023 incorporated by reference in this prospectus, have been so incorporated in reliance on the report of Ziv Haft, Certified Public
Accountants, Isr., BDO Member Firm, an independent registered public accounting firm, incorporated herein by reference, given on the
authority of said firm as experts in auditing and accounting. The report on the consolidated financial statements contains an explanatory
paragraph regarding the Company’s ability to continue as a going concern.
ENFORCEABILITY
OF CIVIL LIABILITIES
We
are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli
experts named in the registration statement of which this prospectus forms a part, a substantial majority of whom reside outside of the
United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and a substantial
of our directors and officers are located outside of the United States, any judgment obtained in the United States against us or any
of our directors and officers may not be collectible within the United States.
We
have been informed by our legal counsel in Israel, Sullivan & Worcester Tel Aviv (Har-Even & Co.), that it may be difficult to
assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on a violation
of U.S. securities laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court
agrees to hear a claim, if U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can
be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law.
Subject
to specified time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain
exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act
and including a monetary or compensatory judgment in a non-civil matter, provided that among other things:
|
● |
the judgment is obtained
after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and
the rules of private international law currently prevailing in Israel; |
|
● |
the judgment is final and
is not subject to any right of appeal; |
|
● |
The prevailing law of the foreign state in which the judgment was rendered
allows for the enforcement of judgments of Israeli courts. However, the court may enforce a foreign judgment, even without reciprocity,
based on the request of the Attorney General, under certain circumstances; |
|
● |
adequate service of process
has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence; |
|
● |
the liabilities under the
judgment are enforceable according to the laws of the State of Israel and the judgment and the enforcement of the civil liabilities
set forth in the judgment is not contrary to the law or public policy in Israel nor likely to impair the security or sovereignty
of Israel; |
|
● |
the judgment was not obtained
by fraud, there was reasonable opportunity for the defendant to present their case, the judgment was given by an authorized court
to issue it under the applicable international private law rules in Israel, and the judgement does not conflict with any other valid
judgments in the same matter between the same parties; |
|
● |
an action between the same
parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; |
|
● |
the judgment is enforceable
according to the laws of Israel and according to the law of the foreign state in which the relief was granted; and |
|
|
|
|
● |
enforcement may be denied
if it could harm the sovereignty or security of Israel. |
If
a foreign judgment is declared enforceable by an Israeli court, it generally will be payable in Israeli currency. The conversion to Israeli
currency will be based on the latest official exchange rate published by the Bank of Israel before the payment date. However, the obligated
party will fulfil its duty by the judgment even if they choose to make the payment in the same foreign currency, subject to the laws
governing the foreign currency applicable at that time.
Pending
collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli CPI plus
interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable
exchange rates.
WHERE
YOU CAN FIND ADDITIONAL INFORMATION
We
have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to the IPO. This prospectus does
not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain
information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents
of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete
descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may
read the document itself for a complete description of its terms. The SEC maintains an Internet website that contains reports and other
information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through
the SEC’s website at www.sec.gov.
We are subject to the information
reporting requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements are filing reports
with the SEC. Those other reports or other information may be inspected without charge at the locations described above. As a foreign
private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our
officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16
of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial
statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However,
we will file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an
annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and will
submit to the SEC, on a Form 6-K, unaudited six-month financial information.
We
maintain a corporate website at www.wearabledevices.co.il. Information contained on, or that can be accessed through, our website does
not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.
We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and
regulations, including, posting any XBRL interactive financial data required to be filed with the SEC and any notices of general meetings
of our shareholders.
INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE
The
SEC allows us to “incorporate by reference” information into this prospectus, which means that we can disclose important
information to you by referring you to other documents which we have filed with the SEC. We are incorporating by reference in this prospectus
the documents listed below:
|
● |
Our Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on March 15, 2024; |
|
● |
Our Reports on Form 6-K,
submitted to the SEC on April 24, 2024, May 16, 2024 (with respect to the first two paragraphs and the section titled “Forward-Looking
Statement Disclaimer” in the press release attached as Exhibit 99.1 to the Report on Form 6-K); June 7, 2024 (with respect
to the first six paragraphs and the section titled “Forward-Looking Statement Disclaimer” in the press release attached
as Exhibit 99.1 to the Report on Form 6-K); August 22, 2024, August 22, 2024 (Report No. 2); September 9, 2024
(with respect to the first two, fourth and fifth paragraphs and the section titled “Forward-Looking Statements” in the press
release attached as Exhibit 99.1 to the Form 6-K); and September 23, 2024 (other than the fifth, sixth and seventh paragraphs in the press
release attached as Exhibit 99.3 to the Form 6-K); and |
|
● |
The description of our
securities contained in Form 8-A, File No. 001-41502, filed with the SEC on September 9, 2022, as amended by Exhibit 2.3 to
our Annual Report on Form 20-F for the fiscal year ended December 31, 2023, filed with the SEC on March 15, 2024, including any further
amendments or reports filed for the purpose of updating such description. |
As
you read the above documents, you may find inconsistencies in information from one document to another. If you find inconsistencies between
the documents and this prospectus, you should rely on the statements made in the most recent document. All information appearing in this
prospectus is qualified in its entirety by the information and financial statements, including the notes thereto, contained in the documents
incorporated by reference herein.
We
will provide to each person, including any beneficial owner, to whom this prospectus is delivered, a copy of these filings, at no cost,
upon written or oral request to us at the following address: 5 Ha-Tnufa St., Yokne’am Illit, 2066736, Israel, Tel: +972.4.6185670,
Attention: Chief Financial Officer.
Up
to 24,574,209 Ordinary Shares
Wearable
Devices Ltd.
PROSPECTUS
,
2024
PART
II
INFORMATION
NOT REQUIRED IN PROSPECTUS
Item 6.
Indemnification of Directors, Officers and Employees
Indemnification
The
Israeli Companies Law 5759-2999, or Companies Law, and the Israeli Securities Law, 5728-1968, or the Securities Law, provide that a company
may indemnify an office holder against the following liabilities and expenses incurred for acts performed by him or her as an office
holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include
a provision authorizing such indemnification:
|
● |
a financial liability imposed
on him or her in favor of another person by any judgment concerning an act performed in his or her capacity as an office holder,
including a settlement or arbitrator’s award approved by a court; |
|
● |
reasonable litigation expenses,
including attorneys’ fees, expended by the office holder (a) as a result of an investigation or proceeding instituted against
him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in
the Companies Law) was filed against such office holder as a result of such investigation or proceeding; and (2) no financial liability
as a substitute for the criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation
or proceeding, or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof
of criminal intent; or (b) in connection with a monetary sanction; |
|
● |
reasonable litigation expenses,
including attorneys’ fees, expended by the office holder or imposed on him or her by a court; (1) in proceedings that the company
institutes, or that another person institutes on the company’s behalf, against him or her; (2) in a criminal proceeding of
which he or she was acquitted; or (3) as a result of a conviction for a crime that does not require proof of criminal intent; and |
|
● |
expenses incurred by an
office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and
reasonable attorneys’ fees. An “Administrative Procedure” is defined as a procedure pursuant to chapters H3 (Monetary
Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee)
or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law. |
The
Companies Law also permits a company to undertake in advance to indemnify an office holder, provided that if such indemnification relates
to financial liability imposed on him or her, as described above, then the undertaking should be limited and shall detail the following
foreseen events and amount or criterion:
|
● |
to events that in the opinion
of the board of directors can be foreseen based on the company’s activities at the time that the undertaking to indemnify is
made; and |
|
● |
in amount or criterion
determined by the board of directors, at the time of the giving of such undertaking to indemnify, to be reasonable under the circumstances. |
We
have entered into indemnification agreements with all of our directors and with all members of our senior management. Each such indemnification
agreement shall provide the office holder with indemnification permitted under applicable law and up to a certain amount, and to the
extent that these liabilities are not covered by directors and officers insurance.
Exculpation
Under
the Companies Law, an Israeli company may not exculpate an office holder from liability for a breach of his or her duty of loyalty, but
may exculpate in advance an office holder from his or her liability to the company, in whole or in part, for damages caused to the company
as a result of a breach of his or her duty of care (other than in relation to distributions), but only if a provision authorizing such
exculpation is included in its articles of association. Our amended and restated articles of association provide that we may exculpate,
in whole or in part, any office holder from liability to us for damages caused to the company as a result of a breach of his or her duty
of care, but prohibit an exculpation, in advance, from liability arising from a company’s transaction in which our controlling
shareholder or office holder has a personal interest. Subject to the aforesaid limitations, under the indemnification agreements, we
exculpate and release our office holders from any and all liability to us related to any breach by them of their duty of care to us to
the fullest extent permitted by law.
Limitations
The
Companies Law provides that the Company may not exculpate or indemnify an office holder nor enter into an insurance contract that would
provide coverage for any liability incurred as a result of any of the following: (1) a breach by the office holder of his or her duty
of loyalty unless (in the case of indemnity or insurance only, but not exculpation) the office holder acted in good faith and had a reasonable
basis to believe that the act would not prejudice us; (2) a breach by the office holder of his or her duty of care if the breach was
carried out intentionally or recklessly (as opposed to merely negligently); (3) any act or omission committed with the intent to derive
an illegal personal benefit; or (4) any fine, monetary sanction, penalty or forfeit levied against the office holder.
Under
the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation
committee and the board of directors (and, with respect to directors and the chief executive officer, by the shareholders). However,
under regulations promulgated under the Companies Law, the insurance of office holders shall not require shareholder approval and may
be approved by only the compensation committee, if the engagement terms are determined in accordance with the company’s compensation
policy that was approved by the shareholders by the same special majority required to approve a compensation policy, provided that the
insurance policy is on market terms and the insurance policy is not likely to materially impact the company’s profitability, assets
or obligations. In addition, under regulations promulgated under the Companies Law, with respect to the insurance of office holders of
a company in which there is a controlling shareholder who is also an office holder, a board approval is also required, subject to meeting
the aforesaid conditions.
Our
amended and restated articles of association permit us to exculpate (subject to the aforesaid limitation), indemnify and insure our office
holders to the fullest extent permitted or to be permitted by the Companies Law.
Item 7.
Recent Sales of Unregistered Securities
Set forth below are the sales
of all securities by the Company since September 2021, which were not registered under the Securities Act. The Company believes that each
of such issuances was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701
and/or Regulation S under the Securities Act. The conversions described below were exempt from registration under Securities Act
in reliance on Section 3(a)(9) of the Securities Act.
In November 2021, we issued
warrants to purchase up to 22,205 Ordinary Shares, issued to a consultant, at an exercise price of $2.25 per share to a consultant, which
all are vested as of September 20, 2024. In September 2022, we issued warrants to purchase up to 23,640 Ordinary Shares, issued to an
advisor, at an exercise price of $4.23 per Ordinary Share.
In
January 2022, we began entering into certain simple agreements for future equity, or the SAFEs, for aggregate proceeds of up to $3 million,
of which we received $500 thousand under the SAFEs. Any amounts received under the SAFEs we enter into will be automatically converted
into our Ordinary Shares in the event we close an Equity Financing (as defined hereinafter) at a discount of 20% from the per share purchase
price in such Equity Financing. An Equity Financing is a transaction or series of transactions with the principal purpose of raising
capital in an aggregate amount of at least $5,000,000, excluding all outstanding (i) SAFEs, and (ii) other convertible securities (if
any), pursuant to which we issue and sell Ordinary Shares at a fixed pre-money valuation. In addition, we agreed to issue to each SAFE
investor a warrant to purchase our Ordinary Shares with an exercise price equal to 150% of the public offering price in such offering
for an aggregate amount of up to 25% of such investor’s SAFE amount. The warrants shall be exercisable until the earlier of: (i)
eighteen (18) months from January 2022; or (ii) in a change of control event, which generally covers (a) transaction in which any person
or group becomes the beneficial owner, directly or indirectly, of more than 50% of our outstanding voting securities with the right to
vote for the election of members of our board of directors, or (b) any reorganization, merger or our consolidation, or (c) a sale, lease
or other disposition of all or substantially all of our assets. Following the consummation of our initial public offering, or IPO, in
September 2022, $100 thousand received under the SAFEs were repaid in cash and $400 thousand were converted into 118,204 Ordinary Shares,
based on the IPO price of $4.23 per Ordinary Share.
In
February 2023, we issued a total of 169,125 Ordinary Shares to Alpha Capital Anstalt, or Alpha, and certain other investors pursuant
to the terms of their April 2021 share purchase agreements with us, as amended by the June 2022 written consent with Alpha.
On June 6, 2024, we entered
into a Standby Equity Purchase Agreement, or the SEPA, with YA II PN, LTD., or YA, pursuant to which we will be able to sell up to $10.0
million of our Ordinary Shares, or the Commitment Amount, at our sole option, any time during the three-year period following the execution
date of the SEPA. Of the Commitment Amount, to date we have sold 3,715,602 Ordinary Shares for aggregate gross proceeds of $1.7 million.
Pursuant to the terms of the SEPA, any Ordinary Shares sold to YA will be priced at 97% of the market price, which is defined as the lowest
daily volume weighted average price of the Ordinary Shares during the three consecutive trading days commencing on the trading day immediately
following our delivery of an advance notice to YA.
Since September 2021, we have
granted to our directors, consultants and service providers, officers, and employees options to purchase an aggregate of 1,259,385 Ordinary
Shares under our 2015 Plan, with an exercise prices ranging between $0.003 and $2.251 per share. As of September 20, 2024, 372,771 options
granted to directors, officers and employees were exercised, and 138,163 options forfeited, such that the total outstanding amount of
options allocated or granted to directors, consultants and service providers, officers and employees as of September 20, 2024 is 1,919,189.
Item 8.
Exhibits and Financial Statement Schedules
Exhibits:
Exhibit Number |
|
Exhibit Description |
|
|
|
3.1 |
|
Amended and Restated Articles of Association of Wearable Devices Ltd. (filed as Exhibit 3.2 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
4.1 |
|
Form of Warrant Agent Agreement (filed as Exhibit 4.3 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference ). |
4.2 |
|
Form of Warrant (filed as Exhibit 4.1 to Form 6-K (File No. 001-41502) filed on September 22, 2022 and incorporated herein by reference). |
4.3 |
|
Form of Underwriter’s Warrant (filed as Exhibit 4.1 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
4.4 |
|
Form of Promissory Note (filed as Exhibit 4.1 to Form 6-K filed on June 7, 2024 and incorporated by reference herein). |
5.1* |
|
Opinion of Sullivan & Worcester Tel Aviv (Har-Even & Co.), Israeli counsel to Wearable Devices Ltd. |
10.1 |
|
Form of Indemnification Agreement (filed as Exhibit 10.1 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
10.2 |
|
Wearable Devices Ltd. 2015 Share Option Plan (filed as Exhibit 10.2 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference ). |
10.3 |
|
First Amendment to Wearable Devices Ltd. 2015 Share Option Plan (filed as Exhibit 10.1 to Form 6-K (File No. 001-41502) filed on August 30, 2023 and incorporated herein by reference). |
10.4 |
|
Share Purchase Agreement, dated April 22, 2021, by and between Wearable Devices Ltd. and Alpha Capital Anstalt (filed as Exhibit 10.3 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
10.5# |
|
Agreement, dated July 16, 2020, by and between Wearable Devices Ltd. and the Israeli Innovation Authority (filed as Exhibit 10.4 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
10.6 |
|
Compensation Policy (filed as Exhibit 10.5 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
10.7 |
|
Senior Credit Facility Agreement, dated July 4, 2022, by and between Wearable Devices Ltd. and L.I.A. Pure Capital Ltd. (filed as Exhibit 10.6 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
10.8 |
|
First Addendum to Senior Agreement, dated July 19, 2022, by and between Wearable Devices Ltd. and L.I.A. Pure Capital Ltd. (filed as Exhibit 10.8 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
10.9 |
|
Standby Equity Purchase Agreement, dated June 6, 2024 (filed as Exhibit 10.1 to Form 6-K filed on June 7, 2024 and incorporated by reference herein). |
10.10 |
|
Wearable Devices Ltd. 2024 Global Equity Incentive Plan (filed as Exhibit 10.1 to Form 6-K (File No. 001-41502) filed on August 22, 2024 and incorporated herein by reference). |
10.11 |
|
Wearable Devices Ltd. 2024 Employee Stock Purchase Plan (filed as Exhibit 10.2 to Form 6-K (File No. 001-41502) filed on August 22, 2024 and incorporated herein by reference). |
21.1 |
|
Subsidiaries of Wearable Devices Ltd. (filed as Exhibit 21.1 to Form F-1 (File No. 333-262838) filed on September 8, 2022 and incorporated herein by reference). |
23.1** |
|
Consent of Ziv Haft, Certified Public Accountants, Isr., BDO member firm, an independent registered public accounting firm. |
23.2* |
|
Consent of Sullivan & Worcester Tel Aviv (Har-Even & Co.) (included in Exhibit 5.1) |
24.1* |
|
Power of Attorney (included in the signature page hereto). |
107* |
|
Filing Fee Table. |
* |
Previously filed |
** |
Filed herewith |
# |
Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. |
Financial
Statement Schedules:
All
financial statement schedules have been omitted because either they are not required, are not applicable or the information required
therein is otherwise set forth in the Company’s financial statements and related notes thereto.
Item 9.
Undertakings
(a) |
The undersigned Registrant
hereby undertakes: |
|
(1) |
To file, during any period
in which offers or sales are being made, a post-effective amendment to this registration statement: |
|
i. |
To include any prospectus
required by section 10(a)(3) of the Securities Act of 1933; |
|
ii. |
To reflect in the prospectus
any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement.
Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities
offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering
range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation
of Registration Fee” table in the effective registration statement; |
|
iii. |
To include any material
information with respect to the plan of distribution not previously disclosed in the registration statement or any material change
to such information in the registration statement. |
|
(2) |
That, for the purpose of
determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration
statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. |
|
(3) |
To remove from registration
by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. |
|
(4) |
To file a post-effective
amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F at the start of any
delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section 10(a)(3)
of the Act need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective amendment,
financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that all other information
in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing, with respect to
registration statements on Form F-3, a post-effective amendment need not be filed to include financial statements and information
required by Section 10(a)(3) of the Act or Item 8.A of Form 20-F if such financial statements and information are contained in periodic
reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange
Act of 1934 that are incorporated by reference in the Form F-3. |
|
(5) |
That, for the purpose of
determining liability under the Securities Act of 1933 to any purchaser: |
|
i. |
If the registrant is relying
on Rule 430B: |
|
A. |
Each prospectus filed by
the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus
was deemed part of and included in the registration statement; and |
|
B. |
Each prospectus required
to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on Rule 430B relating to
an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information required by section 10(a)
of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier of the date
such form of prospectus is first used after effectiveness of the date of the first contract or sale of securities in the offering
described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date and
underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the
registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the
initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part
of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement
or prospectus that is part of the registration statement will, as to a purchaser with a time of contract sale prior to such effective
date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration
statement or made in any such document immediately prior to such effective date; or |
|
ii. |
If the registrant is subject
to Rule 430C, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than
registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part
of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement
made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed
incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a
purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of
first use. |
(b) |
Insofar as indemnification
for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant
pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that
a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
of such issue. |
SIGNATURES
Pursuant to the requirements
of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form F-1 and has duly caused this registration statement on Form F-1 to be signed on its behalf by the undersigned, thereunto
duly authorized, in Yokne’am Illit, Israel, on September 23, 2024.
|
Wearable Devices Ltd. |
|
|
|
By: |
/s/
Asher Dahan |
|
|
Asher Dahan |
|
|
Chief Executive Officer |
Pursuant
to the requirements of the Securities Act of 1933, this amendment to the registration statement on Form F-1 has been signed by the following
persons in the capacities and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Asher Dahan |
|
Chief Executive Officer, Chairman of Board of Directors |
|
September 23, 2024 |
Asher Dahan |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Alon Mualem |
|
Chief Financial Officer |
|
September 23, 2024 |
Alon Mualem |
|
(Principal Financial and Accounting Officer) |
|
|
|
|
|
|
|
* |
|
Director |
|
September 23, 2024 |
Eli Bachar |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
September 23, 2024 |
Yaacov Goldman |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
September 23, 2024 |
Ilana Lurie |
|
|
|
|
|
|
|
|
|
* |
|
Director |
|
September 23, 2024 |
Guy Wagner |
|
|
|
|
*By: |
/s/ Asher Dahan |
|
|
Asher Dahan |
|
|
Attorney-in-Fact |
|
SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES
Pursuant to the Securities
Act of 1933, as amended, the undersigned, Mudra Wearable, Inc., the duly authorized representative in the United States of Wearable Devices
Ltd., has signed this registration statement on September 23, 2024.
|
Mudra Wearable, Inc. |
|
|
|
By: |
/s/
Asher Dahan |
|
Name: |
Asher Dahan |
|
Title: |
President, Director |
II-7
Exhibit 23.1
Consent of Independent Registered Public Accounting
Firm
Wearable Devices Ltd.
We hereby consent to the incorporation by reference
in this Post- Effective Amendment No. 1 to the Registration Statement on form F-1 of Wearable Devices Ltd. (“the Company”) of
our report dated March 13, 2024, relating to the consolidated financial statements which appears in Wearable Devices Ltd.’s Annual
Report on Form 20-F for the year ended December 31, 2023. Our report contains an explanatory paragraph regarding the Company’s ability
to continue as a going concern.
We also consent to the reference to us under the
caption “Experts” in such Registration Statement.
/s/ Ziv Haft |
|
Ziv Haft |
|
Certified Public Accountants (Isr.) |
|
BDO Member Firm |
|
September 23, 2024 |
|
|
|
Tel Aviv, Israel |
|
Wearable Devices (NASDAQ:WLDSW)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Wearable Devices (NASDAQ:WLDSW)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024